Young Eun Lee1, Seung Ah Choi1, Pil Ae Kwack1, Hak Jae Kim1, Il Han Kim1, Kyu-Chang Wang1, Ji Hoon Phi1, Ji Yeoun Lee1, Sangjoon Chong1, Sung-Hye Park1, Kyung Duk Park1, Do Won Hwang1, Kyeung Min Joo1, Seung-Ki Kim1. 1. Division of Pediatric Neurosurgery, Pediatric Clinical Neuroscience Center, Seoul National University Children's Hospital, Seoul National University College of Medicine, Seoul, South Korea; Adolescent Cancer Center, Seoul National University Cancer Hospital, Seoul, South Korea; Department of Radiation Oncology, Seoul National University Hospital, Seoul, South Korea; Department of Anatomy, Seoul National University College of Medicine, Seoul, South Korea; Department of Pathology, Seoul National University College of Medicine, Seoul, South Korea; Department of Pediatrics, Seoul National University Children's Hospital, Seoul, South Korea; Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, South Korea; Department of Health Science and Technology, Samsung Advanced Institute for Health Sciences and Technology, SungKyunKwan University, Seoul, South Korea; Department of Anatomy and Cell Biology, SungKyunKwan University School of Medicine, Suwon, South Korea; Single Cell Network Research Center, Sungkyunkwan University School of Medicine, Suwon, South Korea.
Abstract
BACKGROUND: Atypical teratoid/rhabdoid tumor (AT/RT) is one of the most common malignant brain tumors in infants. Although cancer stem cells of AT/RT express aldehyde dehydrogenase (ALDH), effective chemotherapies against AT/RT have not been established. Here, we examined radiosensitizing effects of disulfiram (DSF), an irreversible inhibitor of ALDH against AT/RT for a novel therapeutic method. METHODS: Patient-derived primary cultured AT/RT cells (SNU.AT/RT-5 and SNU.AT/RT-6) and established AT/RT cell lines (BT-12 and BT-16) were used to assess therapeutic effects of combining DSF with radiation treatment (RT). Survival fraction by clonogenic assay, protein expression, immunofluorescence, and autophagy analysis were evaluated in vitro. Antitumor effects of combining DSF with RT were verified by bioluminescence imaging, tumor volume, and survival analysis in vivo. RESULTS: The results demonstrated that DSF at low concentration enhanced the radiosensitivity of AT/RT cells with reduction of survival fraction to 1.21‒1.58. DSF increased DNA double-strand break (γ-H2AX, p-DNA-PKcs, and p-ATM), apoptosis (cleaved caspase-3), autophagy (LC3B), and cell cycle arrest (p21) in irradiated AT/RT cells, while it decreased anti-apoptosis (nuclear factor-kappaB, Survivin, and B-cell lymphoma 2 [Bcl2]). In vivo, DSF and RT combined treatment significantly reduced tumor volumes and prolonged the survival of AT/RT mouse models compared with single treatments. The combined treatment also increased γ-H2AX, cleaved caspase-3, and LC3B expression and decreased ALDH1, Survivin, and Bcl2 expression in vivo. CONCLUSIONS: DSF and RT combination therapy has additive therapeutic effects on AT/RT by potentiating programmed cell death, including apoptosis and autophagy of AT/RT cells. We suggest that DSF can be applied as a radiosensitizer in AT/RT treatment.
BACKGROUND: Atypical teratoid/rhabdoid tumor (AT/RT) is one of the most common malignant brain tumors in infants. Although cancer stem cells of AT/RT express aldehyde dehydrogenase (ALDH), effective chemotherapies against AT/RT have not been established. Here, we examined radiosensitizing effects of disulfiram (DSF), an irreversible inhibitor of ALDH against AT/RT for a novel therapeutic method. METHODS: Patient-derived primary cultured AT/RT cells (SNU.AT/RT-5 and SNU.AT/RT-6) and established AT/RT cell lines (BT-12 and BT-16) were used to assess therapeutic effects of combining DSF with radiation treatment (RT). Survival fraction by clonogenic assay, protein expression, immunofluorescence, and autophagy analysis were evaluated in vitro. Antitumor effects of combining DSF with RT were verified by bioluminescence imaging, tumor volume, and survival analysis in vivo. RESULTS: The results demonstrated that DSF at low concentration enhanced the radiosensitivity of AT/RT cells with reduction of survival fraction to 1.21‒1.58. DSF increased DNA double-strand break (γ-H2AX, p-DNA-PKcs, and p-ATM), apoptosis (cleaved caspase-3), autophagy (LC3B), and cell cycle arrest (p21) in irradiated AT/RT cells, while it decreased anti-apoptosis (nuclear factor-kappaB, Survivin, and B-cell lymphoma 2 [Bcl2]). In vivo, DSF and RT combined treatment significantly reduced tumor volumes and prolonged the survival of AT/RT mouse models compared with single treatments. The combined treatment also increased γ-H2AX, cleaved caspase-3, and LC3B expression and decreased ALDH1, Survivin, and Bcl2 expression in vivo. CONCLUSIONS: DSF and RT combination therapy has additive therapeutic effects on AT/RT by potentiating programmed cell death, including apoptosis and autophagy of AT/RT cells. We suggest that DSF can be applied as a radiosensitizer in AT/RT treatment.
Authors: Jonathon Torchia; Daniel Picard; Lucie Lafay-Cousin; Cynthia E Hawkins; Seung-Ki Kim; Louis Letourneau; Young-Shin Ra; King Ching Ho; Tiffany Sin Yu Chan; Patrick Sin-Chan; Christopher P Dunham; Stephen Yip; Ho-Keung Ng; Jian-Qiang Lu; Steffen Albrecht; José Pimentel; Jennifer A Chan; Gino R Somers; Maria Zielenska; Claudia C Faria; Lucia Roque; Berivan Baskin; Diane Birks; Nick Foreman; Douglas Strother; Almos Klekner; Miklos Garami; Peter Hauser; Tibor Hortobágyi; Laszló Bognár; Beverly Wilson; Juliette Hukin; Anne-Sophie Carret; Timothy E Van Meter; Hideo Nakamura; Helen Toledano; Iris Fried; Daniel Fults; Takafumi Wataya; Chris Fryer; David D Eisenstat; Katrin Scheineman; Donna Johnston; Jean Michaud; Shayna Zelcer; Robert Hammond; David A Ramsay; Adam J Fleming; Rishi R Lulla; Jason R Fangusaro; Nongnuch Sirachainan; Noppadol Larbcharoensub; Suradej Hongeng; Muhammad Abrar Barakzai; Alexandre Montpetit; Derek Stephens; Richard G Grundy; Ulrich Schüller; Theodore Nicolaides; Tarik Tihan; Joanna Phillips; Michael D Taylor; James T Rutka; Peter Dirks; Gary D Bader; Monika Warmuth-Metz; Stefan Rutkowski; Torsten Pietsch; Alexander R Judkins; Nada Jabado; Eric Bouffet; Annie Huang Journal: Lancet Oncol Date: 2015-04-14 Impact factor: 41.316
Authors: Joanne M Hilden; Sharon Meerbaum; Peter Burger; Jonathan Finlay; Anna Janss; Bernd W Scheithauer; Andrew W Walter; Lucy B Rorke; Jaclyn A Biegel Journal: J Clin Oncol Date: 2004-07-15 Impact factor: 44.544
Authors: Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff Journal: Lancet Oncol Date: 2009-03-09 Impact factor: 41.316
Authors: Xueqing Lun; J Connor Wells; Natalie Grinshtein; Jennifer C King; Xiaoguang Hao; Ngoc-Ha Dang; Xiuling Wang; Ahmed Aman; David Uehling; Alessandro Datti; Jeffrey L Wrana; Jacob C Easaw; Artee Luchman; Samuel Weiss; J Gregory Cairncross; David R Kaplan; Stephen M Robbins; Donna L Senger Journal: Clin Cancer Res Date: 2016-03-22 Impact factor: 12.531
Authors: I Versteege; N Sévenet; J Lange; M F Rousseau-Merck; P Ambros; R Handgretinger; A Aurias; O Delattre Journal: Nature Date: 1998-07-09 Impact factor: 49.962
Authors: M S Brassesco; G M Roberto; A G Morales; J C Oliveira; L E A Delsin; J A Pezuk; E T Valera; C G Carlotti; E M Rego; H F de Oliveira; C A Scrideli; K Umezawa; L G Tone Journal: Chemother Res Pract Date: 2013-02-21
Authors: Do Won Hwang; Yeona Jin; Do Hun Lee; Han Young Kim; Han Na Cho; Hye Jin Chung; Yunwoong Park; Hyewon Youn; Seung Jin Lee; Hong J Lee; Seung U Kim; Kyu-Chang Wang; Dong Soo Lee Journal: PLoS One Date: 2014-09-08 Impact factor: 3.240
Authors: Hyeon Kang Koh; Soo Yeon Seo; Jin Ho Kim; Hak Jae Kim; Eui Kyu Chie; Seung-Ki Kim; Il Han Kim Journal: Cancer Res Treat Date: 2018-08-13 Impact factor: 4.679
Authors: Karolina Nemes; Pascal D Johann; Stefanie Tüchert; Patrick Melchior; Christian Vokuhl; Reiner Siebert; Rhoikos Furtwängler; Michael C Frühwald Journal: Cancer Manag Res Date: 2022-02-09 Impact factor: 3.989